CRMD - CorMedix Inc.

6.72
0.160   2.381%

Share volume: 1,820,853
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$6.56
0.16
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 25%
Dept financing 8%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.02%
1 Month
-9.56%
3 Months
-42.76%
6 Months
-48.66%
1 Year
-36.54%
2 Year
90.91%
Key data
Stock price
$6.72
P/E Ratio 
N/A
DAY RANGE
$6.55 - $6.86
EPS 
$2.25
52 WEEK RANGE
$5.60 - $17.43
52 WEEK CHANGE
-$38.74
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
79.050 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,209,101
AVERAGE 30 VOLUME 
$1,696,874
Company detail
CEO: Joseph Todisco
Region: US
Website: cormedix.com
Employees: 30
IPO year: 2010
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

CorMedix Inc. focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings.

Recent news